---
id: gordian-biotechnology
slug: gordian-biotechnology
entity_type: commercial
status: operational
data_completeness: high
last_researched: 2025-01-27
researcher: AI Assistant
version: 1.0
name: Gordian Biotechnology
description: To cure age-related diseases, enabling people to live longer, healthier lives and become more capable each day. Gordian Biotechnology aims to identify targets and therapies for complex age-related diseases that have the highest probability of success in human clinical trials through its innovative in vivo screening platform.
mission: To cure age-related diseases, enabling people to live longer, healthier lives and become more capable each day. Gordian Biotechnology aims to identify targets and therapies for complex age-related diseases that have the highest probability of success in human clinical trials through its innovative in vivo screening platform.
entity_data:
  name: Gordian Biotechnology
  focus: Development of therapies for complex age-related diseases using high-throughput in vivo screening platform
  status: operational
  founded: 2018
  website: "https://www.gordian.bio/"
  industry: Biotechnology
  employees:
  note: Company actively hiring, exact number not publicly disclosed
  as_of: 2024
  legal_name: Gordian Biotechnology, Inc.
  headquarters:
  city: South San Francisco
  state: California
  address: 486 Cabot Rd, South San Francisco, CA 94080
  country: USA
taxonomy:
  geography: USA
  ai_technology:
  - Machine Learning
  - Transcriptome Analysis
  - Pathway Analysis
  - Single-Cell RNA Sequencing Analysis
  - Predictive Modeling
  primary_focus:
  - Age-Related Diseases
  - Therapeutic Discovery
  - In Vivo Screening
  aging_approach:
  - Therapeutic Discovery
  - Platform Technology
  - Predictive Screening
  target_biology:
  - Age-Related Diseases
  - Osteoarthritis
  - Complex Age-Related Conditions
  development_stage: platform_validation
  organization_type: commercial
  organization_subtype: operational
  therapeutic_modality:
  - Platform Technology
  - Multiple Modalities
organizations:
  -
    name: Gordian Biotechnology
    role: primary
    org_type: company
    legal_name: Gordian Biotechnology, Inc.
    founded: 2018
    website: "https://www.gordian.bio/"
    status: operational
    role_description: Primary organization developing the platform
products:
  -
    name: Gordian Platform
    type: platform
    status: Operational
    development_stage: Platform validation and therapeutic discovery
links:
  -
    url: "https://longevity.openclinics.ru/blog/peredovye-tekhnologii-zamedleniya-stareniya-gordian-biotechnology/"
    type: article
    title: "Передовые технологии замедления старения: Gordian Biotechnology"
  -
    url: "https://www.eurekalert.org/news-releases/1093952"
    type: press_release
    title: 12th Aging Research & Drug Discovery Meeting 2025 - Gordian Sponsorship
  -
    url: "https://lu.ma/6ygjruzo"
    type: event
    title: Gordian Biotechnology and age¹ Event - Brain Aging Research
  -
    url: "https://ghpnews.digital/winners/gordian-biotechnology/"
    type: award
    title: Gordian Biotechnology - GHP News Award
  -
    url: "https://longevity.technology/news/gordian-launches-with-60m-and-platform-that-predicts-outcomes-in-age-related-diseases/"
    type: news_article
    title: Gordian Launches with $60M and Platform That Predicts Outcomes in Age-Related Diseases
  -
    url: "https://www.prnewswire.com/news-releases/gordian-biotechnology-introduces-high-throughput-in-vivo-screening-platform-to-discover-therapies-and-better-predict-human-outcomes-for-age-related-diseases-302128574.html"
    type: press_release
    title: Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform
  -
    url: "https://www.gordian.bio/company/"
    type: company_website
    title: Gordian Biotechnology - Company Information
  -
    url: "https://www.gordian.bio/science/"
    type: company_website
    title: Gordian Biotechnology - Science Platform
---

# Gordian Biotechnology

## Description

To cure age-related diseases, enabling people to live longer, healthier lives and become more capable each day. Gordian Biotechnology aims to identify targets and therapies for complex age-related diseases that have the highest probability of success in human clinical trials through its innovative in vivo screening platform.

## Mission

To cure age-related diseases, enabling people to live longer, healthier lives and become more capable each day. Gordian Biotechnology aims to identify targets and therapies for complex age-related diseases that have the highest probability of success in human clinical trials through its innovative in vivo screening platform.

## Company Information

**Legal Name**: Gordian Biotechnology, Inc.
**Founded**: 2018
**Industry**: Biotechnology
**Employees**: {"note":"Company actively hiring, exact number not publicly disclosed","as_of":"2024"}
**Focus**: Development of therapies for complex age-related diseases using high-throughput in vivo screening platform
**Website**: https://www.gordian.bio/

## Scientific Background

```yaml
ai_necessity: AI is essential for analyzing the massive amounts of transcriptome data generated from high-throughput screening. Machine learning enables identification of patterns and predictive signatures that would be impossible to detect through manual analysis.
in_vivo_advantage: In vivo screening in animals that naturally develop age-related diseases provides more physiologically relevant models than traditional laboratory animals with artificially induced diseases. This approach captures complex biological interactions and disease progression similar to humans.
transcriptome_analysis: Transcriptome analysis provides comprehensive view of cellular responses to therapies, revealing effects across multiple pathways simultaneously. Single-cell resolution enables precise correlation between therapeutic exposure and biological response.
aging_disease_complexity: "Age-related diseases involve complex, multi-pathway biological processes that are difficult to model and predict. Traditional drug discovery approaches often fail because they focus on single disease mechanisms and use artificial models that don't reflect human biology."
mosaic_screening_innovation: Mosaic screening represents a paradigm shift in therapeutic discovery, enabling simultaneous testing of hundreds of therapies in single animals. This approach dramatically increases throughput while maintaining biological context and reducing animal use.
```

## Organizations

### Gordian Biotechnology
**Legal Name**: Gordian Biotechnology, Inc.
**Role in Project**: primary
**Role Description**: Primary organization developing the platform
**Organization Type**: company
**Status**: operational
**Founded**: 2018
**Website**: https://www.gordian.bio/
**Description**: Biotechnology company developing therapies for complex age-related diseases using high-throughput in vivo screening platform
**Focus**: Development of therapies for complex age-related diseases using high-throughput in vivo screening platform

## Locations

### Gordian Biotechnology Headquarters
**Type**: headquarters
**Address**: 486 Cabot Rd, South San Francisco, CA 94080
**City**: South San Francisco
**State/Region**: California
**Country**: USA
**Organizations**: Gordian Biotechnology

## Products

### Gordian Platform
**Alternative Names**: Gordian In Vivo Screening Platform, High-Throughput In Vivo Screening Platform
**Type**: platform
**Status**: Operational
**Development Stage**: Platform validation and therapeutic discovery
**Role in Project**: primary
**Relationship Description**: Primary platform technology developed by Gordian Biotechnology
**Description**: A three-component in vivo screening platform designed to discover therapies and better predict human outcomes for age-related diseases. The platform enables high-throughput screening of hundreds of therapies in individual Patient Avatars, with AI-powered analysis of transcriptome data to assess therapeutic effects on multiple cellular pathways.
**Indications**: [
  {
    "primary": "Age-related diseases",
    "examples": [
      "Osteoarthritis",
      "Other complex age-related conditions"
    ]
  }
]
**Components**:
```yaml
-
  name: Patient Avatars
  description: Animal models that most accurately reflect human patient biology with target diseases, often with naturally acquired pathologies. These models serve as avatars for human patients, allowing for more predictive preclinical testing.
  methodology: Uses animals that naturally develop age-related diseases similar to humans, providing more physiologically relevant models than traditional laboratory animals
-
  name: Mosaic Screening
  description: "A high-throughput screening approach that creates a unified library of hundreds of therapies and tests them in vivo on individual Patient Avatars simultaneously. Creates a 'mosaic' of different cells that have received different barcoded therapies within a single animal."
  methodology: Hundreds of barcoded therapies are introduced into a single animal, allowing simultaneous evaluation of multiple therapeutic candidates in one Patient Avatar, dramatically increasing screening throughput
-
  name: Pythia
  description: AI-powered transcriptome analysis system that analyzes the entire transcriptome to determine how each therapy affects dozens of cellular pathways in a living organism. Instead of focusing on a single disease hypothesis, Pythia evaluates the comprehensive impact of each therapy across multiple pathways.
  methodology: Uses machine learning and AI to interpret single-cell transcriptome data, assessing the in vivo impact of each therapy on multiple cellular pathways simultaneously
```
**Technical Details**:
```yaml
awards:
  -
    year: 2022
    award: Most Advanced In Vivo Platform for Therapeutic Screening
    description: Recognized for innovative in vivo screening platform
validation_data:
  therapies_advanced:
  validation: Platform validated for identifying promising therapeutic candidates
  description: Dozens of therapies advanced to ex vivo studies on human samples
  horses_osteoarthritis:
  accuracy: 80% accuracy in predicting clinical outcomes
  description: Successfully screened hundreds of therapies on horses with naturally developed osteoarthritis
  significance: "Demonstrated platform's ability to predict human clinical outcomes with high accuracy"
```

## Key People

### Francisco LePort
**Participation Type**: leadership
**Role in Project**: Chief Executive Officer (CEO)
**Involvement Period**: {"end":null,"start":"2018-01","status":"ongoing"}
**Responsibilities**:
- Overall leadership and strategic direction of the company
**Expertise**: Biotechnology leadership, drug development
**Biography**: Co-founder and CEO of Gordian Biotechnology. Leads the company's mission to develop therapies that allow people to become more capable as they age, focusing on curing age-related diseases to enable longer, healthier lives.

### Martin Borch Jensen
**Title**: Chief Scientific Officer (CSO)
**Participation Type**: leadership
**Role in Project**: Chief Scientific Officer (CSO)
**Involvement Period**: {"end":null,"start":"2018-01","status":"ongoing"}
**Responsibilities**:
- Scientific leadership, platform development, research strategy
**Expertise**: Scientific leadership, platform development, research strategy
**Biography**: Chief Scientific Officer emphasizing the importance of modeling complex aging biology in rare animal models to increase the probability of clinical success

### Christine Van Vlaeselaer
**Title**: Vice President of Operations
**Participation Type**: leadership
**Role in Project**: Vice President of Operations
**Involvement Period**: {"end":null,"start":"2018-01","status":"ongoing"}
**Responsibilities**:
- R&D operations management
**Expertise**: R&D operations management
**Biography**: VP of Operations with expertise in neuroscience and life sciences consulting, leading R&D operations at Gordian

## Links

### [Передовые технологии замедления старения: Gordian Biotechnology](https://longevity.openclinics.ru/blog/peredovye-tekhnologii-zamedleniya-stareniya-gordian-biotechnology/)
**Type**: article
**Relevance**: secondary
**Category**: reference
**Publisher**: Longevity OpenClinics
**Description**: Article about Gordian Biotechnology's platform and approach to aging research

### [12th Aging Research & Drug Discovery Meeting 2025 - Gordian Sponsorship](https://www.eurekalert.org/news-releases/1093952)
**Type**: press_release
**Relevance**: secondary
**Category**: reference
**Publisher**: EurekAlert
**Publication Date**: 2025-11-01
**Description**: Press release about ARDD 2025 conference sponsorship

### [Gordian Biotechnology and age¹ Event - Brain Aging Research](https://lu.ma/6ygjruzo)
**Type**: event
**Relevance**: secondary
**Category**: reference
**Publisher**: Lu.ma
**Publication Date**: 2025-10-01
**Description**: Event co-hosted with age¹ venture fund discussing brain aging research

### [Gordian Biotechnology - GHP News Award](https://ghpnews.digital/winners/gordian-biotechnology/)
**Type**: award
**Relevance**: secondary
**Category**: reference
**Publisher**: GHP News
**Publication Date**: 2022-01-01
**Description**: Award for Most Advanced In Vivo Platform for Therapeutic Screening

### [Gordian Launches with $60M and Platform That Predicts Outcomes in Age-Related Diseases](https://longevity.technology/news/gordian-launches-with-60m-and-platform-that-predicts-outcomes-in-age-related-diseases/)
**Type**: news_article
**Relevance**: primary
**Category**: source
**Publisher**: Longevity Technology
**Publication Date**: 2024-04-01
**Description**: News article about Gordian's platform launch and funding announcement

### [Gordian Biotechnology Introduces High-Throughput In Vivo Screening Platform](https://www.prnewswire.com/news-releases/gordian-biotechnology-introduces-high-throughput-in-vivo-screening-platform-to-discover-therapies-and-better-predict-human-outcomes-for-age-related-diseases-302128574.html)
**Type**: press_release
**Relevance**: primary
**Category**: source
**Publisher**: PR Newswire
**Publication Date**: 2024-04-01
**Description**: Press release announcing platform launch, validation results, and $60 million funding round

### [Gordian Biotechnology - Company Information](https://www.gordian.bio/company/)
**Type**: company_website
**Relevance**: primary
**Category**: source
**Publisher**: Gordian Biotechnology
**Description**: Information about company leadership, mission, and culture

### [Gordian Biotechnology - Science Platform](https://www.gordian.bio/science/)
**Type**: company_website
**Relevance**: primary
**Category**: source
**Publisher**: Gordian Biotechnology
**Description**: Detailed information about Patient Avatars, Mosaic Screening, and Pythia platform components

## Financials

### funding
**Amount**: $60 million USD
**Amount (Numeric)**: 60000000
**Funding Date**: 2024-04-01
**Source**: Venture Capital
**Funding Type**: Venture Capital Funding
**Description**: Series funding round to support platform development and therapeutic discovery
**Details**:
```yaml
investors:
  - The Longevity Fund
  - Arctica Ventures
  - Athos Service GmbH
  - Gigafund
  - Founders Fund
  - Fifty Years
  - Thomas Ebeling (former CEO of Novartis)
use_of_funds: Platform development, therapeutic screening, and advancement of candidates to clinical development
announcement_date: April 2024
```

## Events

### Company Founding
**Date**: 2018-01-01
**Type**: foundation
**Description**: Gordian Biotechnology founded to develop therapies for complex age-related diseases using innovative in vivo screening platform

### Award: Most Advanced In Vivo Platform for Therapeutic Screening
**Date**: 2022-01-01
**Type**: award
**Description**: Received award for Most Advanced In Vivo Platform for Therapeutic Screening
**Details**:
```yaml
significance: Recognition of platform innovation and capabilities
```

### Platform Launch and Funding
**Date**: 2024-04-01
**Type**: launch
**Description**: Announced high-throughput in vivo screening platform and raised $60 million in funding
**Details**:
```yaml
significance: Major milestone demonstrating platform validation and investor confidence
```

### Conference Sponsorship: ARDD 2025
**Date**: 2025-11-01
**Type**: conference
**Description**: Sponsored 12th Aging Research & Drug Discovery (ARDD) Meeting 2025, the world's largest aging research conference in the biopharmaceutical industry
**Details**:
```yaml
significance: Active participation in aging research community
```

## Partnerships

### research
**Date**: 2025-10-01
**Focus**: Aging research and brain aging
**Description**: Co-hosted event in San Francisco discussing research on mapping and decoding brain aging processes
**Partner Organizations**:
- age¹ (partner)
  - Collaboration partner for aging research event
**Details**:
```yaml
type: Collaboration
```
